כולבם 250 מג 以色列 - 希伯来文 - Ministry of Health

כולבם 250 מג

megapharm ltd - cholic acid - קפסולה קשיחה - cholic acid 250 mg - cholic acid

כולבם 50 מג 以色列 - 希伯来文 - Ministry of Health

כולבם 50 מג

megapharm ltd - cholic acid - קפסולה קשיחה - cholic acid 50 mg - cholic acid

Introducer & pacing leads 以色列 - 希伯来文 - Ministry of Health

introducer & pacing leads

שילה חדשנות רפואית בע"מ - רופא - arterial introducer

pouches & reels for sterilization 以色列 - 希伯来文 - Ministry of Health

pouches & reels for sterilization

תרופארם שיווק 1985 בע"מ - אחר - שרוולים ושקיות לסטריליזציה

BOP POUCHES 以色列 - 希伯来文 - Ministry of Health

bop pouches

תרופארם שיווק 1985 בע"מ - צוות טכני - מפעלים, בתי חולים

IVD Medical Products & Reagents for blood bank : Galileo, Neo :Analyzer, Reagents, Solutions, Consumables and Service Parts 以色列 - 希伯来文 - Ministry of Health

ivd medical products & reagents for blood bank : galileo, neo :analyzer, reagents, solutions, consumables and service parts

איילקס ביוטק בע"מ - מומחה - מערכות אוטומטיות ממוחשבות ומגיבים לעבודה ידנית לסיווג קבוצות דם וסקר נוגדנים הכוללות: מיכשור,מגיבים,בקרים ונלווים

אורוקורט E 以色列 - 希伯来文 - Ministry of Health

אורוקורט e

taro pharmaceutical industries ltd - lidocaine hydrochloride monohydrate; triamcinolone acetonide - פסטה - lidocaine hydrochloride monohydrate 3 g / 100 g; triamcinolone acetonide 0.1 g / 100 g - triamcinolone - triamcinolone - adjunctive treatment and temporary relief of symptoms associated with inflammatory lesions in the oral cavity.

Medical Devices for Invasive Cardiology procedures 以色列 - 希伯来文 - Ministry of Health

medical devices for invasive cardiology procedures

גאמידה בע"מ - מומחה - שימוש לפעולות אלקטרופזיולוגיות פולשניות ; קוצב דו-חדרי, צריבה של פרפור פרוזדורים

נוקספיל תרחיף 以色列 - 希伯来文 - Ministry of Health

נוקספיל תרחיף

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

נוקספיל תרחיף 以色列 - 希伯来文 - Ministry of Health

נוקספיל תרחיף

merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti